Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model

MCM Mah-Becherel¹, J Céraline¹, G Deplanque¹, M-P Chenard², J-P Bergerat¹, J-P Cazenave³ and C Klein-Soyer*¹

¹Laboratoire de Cancérologie Expérimentale et de Radiobiologie, Institut de Recherche contre les Cancers de l’Appareil Digestif, Hôpitaux Universitaires de Strasbourg, BP 426, 67091 Strasbourg, France; ²Anatomie pathologie Générale, Hôpitaux Universitaires de Strasbourg, BP 426, 67091 Strasbourg, France; ³INSERM U. 311, Etablissement Français du Sang-Alsace, 10, rue Spielmann, BP 36, 67065 Strasbourg Cedex, France

Neovascularisation is a key step in tumour growth and establishment of distant metastases. We have recently demonstrated that the thienopyridine SR 25989 an enantiomer of the anti-aggregant clopidogrel (Plavix®) lacking anti-aggregant activity, inhibits endothelial cell proliferation in vitro by increasing the expression of endogenous thrombospondin-1, a natural potent inhibitor of angiogenesis. The anti-angiogenic effect of SR 25989 was further assessed in vitro in a quantitative assay of angiogenesis comprising a fragment of rat aorta embedded in a fibrin gel and in vivo in a pulmonary metastatic model using C57BL/6 mice inoculated in the foot pad with the highly metastatic melanoma cell line B16 F10. SR 25989 induced a dose dependent inhibition of spontaneous microvessel development in vitro reaching half maximal inhibition at around less than 50 µM and caused platelet derived growth factor induced angiogenesis to regress as a function of thienopyridine concentration. In vivo, SR 25989 did not alter significantly the growth rate of the primary tumour in the foot pad and did not inhibit development of inguinal nodes which appeared after amputation. However, the number and size of lung metastases were reduced in treated animals when examined at the time of sacrifice. In addition, the few metastases over 1 mm³ did not show any neovascularisation, as confirmed by negative von Willebrand immunostaining and in contrast to intense vascularisation seen in metastases developed by control mice. These results confirm that SR 25989 possesses potent anti-angiogenic properties and is able to inhibit metastatic dissemination and growth. The lack of effect on the primary tumour and inguinal nodes illustrates the complexity of the mechanisms involved in tumoral neo-angiogenesis and points out the possibility for distinct processes leading to neovascularisation in primary tumour as opposed to metastases.

British Journal of Cancer (2002) 86, 803 – 810. DOI: 10.1038/sj/bjc/6600142 www.bjcancer.com

Keywords: B16 F10 melanoma; metastasis; thienopyridine; SR 25989; anti-angiogenesis

For three decades angiogenesis has been recognised as a key step in tumour growth and metastasis development (Folkman, 1995a,b). The great cellular and genetic diversity of solid tumours is responsible for the wide disparity of their responses towards chemical/radiotherapeutic treatments. One common element among their characteristics is the tumour vasculature which shares identical features throughout the tumoral tissues and which is different from the vasculature of normal tissues. The tumour vasculature has an immature endothelium and forms an abnormal network of leaky vessels with chaotic flow (Denekamp et al, 1998). Below a critical size of 1 – 2 mm³ metastases are supposed not to need to be vascularised for their nutritive supply (Folkman, 1990). However some tumours can grow above this size without inducing angiogenesis by using some alternative strategies such as vessel cooption (Holash et al, 1999) or tumour cells forming their own channels (Barinaga, 1999; Maniotis et al, 1999). Despite these particularities, it appears that tumour angiogenesix now represents a promising therapeutic target for the treatment of cancer (Deplanque and Harris, 2000; Kerbel, 2000; Liekens et al, 2001). Among the abundance of molecules to which an angiostatic or anti-angiogenic property has been assigned, some of them have today reached the stage of the clinical assay. Although the mechanisms of these molecules are way from being all elucidated, several strategies have been drawn: (i) inhibition of signalling pathways – by targeting tyrosine kinase receptors involving growth factors such as basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) which are strong inducers of angiogenesis (Laird et al, 2000; Pegram and Slamon, 2000), – by inhibition of the growth factors themselves (Pepper et al, 1996; Lee et al, 2000), – or by inhibiting adhesion molecule receptors like the integrin αv β3 which is essentially expressed in growing capillaries (Brooks et al, 1994; Gutheil et al, 2000); (ii) inhibition of tumour neovascularisation by means of endogenous polypeptide fragments or proteins having anti-angiogenic or angiostatic properties: molecules such as angiotatin, an internal fragment of plasminogen (O’Reilly et al, 1994), endostatin, a fragment of collagen XVIII (O’Reilly et al, 1997), platelet factor 4 (PF4), (Maione et al, 1990), interferons (Ezekowitz et al, 1992) and thrombospondin-1 (TSP-1), a matricellular protein (Bornstein, 1995) appear among these molecules (reviewed in Sage, 1997; Carmeliet and Jain, 2000; Kerbel, 2000); (iii) reassessment of molecules which were not originally developed as anti-tumour angiogenesis drugs but for which anti-angiogenic properties were
Cell culture and proliferation assay

B16 F10 cells were routinely grown in RPMI 1640, 2 mM glutamine, 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin, and 10% FCS unless otherwise stated. Exponentially growing cells were sparsely seeded (5000 cells per cm²) in 96-mutidwell plates in the presence of 10% FCS. After 24 h when cell adhesion was achieved, the medium was changed and the serum concentration set to 10, 5 or 2% FCS. SR 25989 was added at 37.5 and 150 μM. These two concentrations were chosen as previous works have shown that SR 25989 up to 37.5 μM had no effect on the proliferation of human endothelial cells or skin fibroblasts but displayed significant inhibitory activity in the range of 75–150 μM (Klein-Soyer et al., 1994, 1997). The medium was further changed at days 4 and 7 in identical conditions and the drug was added at each medium change. At days 4, 7 and 10 representative samples were fixed in 2% paraformaldehyde solution and B16 F10 proliferation was estimated by quantification of crystal violet staining of the cells with a microplate reader (Gillies et al., 1986).

Clonogenic assay

The effects of SR 25989 on cell survival was investigated in a clonogenic assay as follows: exponentially growing B16 F10 cells were used for the experiments. Single cell suspensions were prepared from B16 F10 cultures which had been submitted to increasing concentrations of SR 25989 (0 to 400 μM) for 4 h in medium containing 10% FCS. The suspensions were serially diluted in medium containing 10% FCS and the different B16 F10 cell dilutions were seeded in triplicate in 10 mm Petri dishes. After 7 to 10 days incubation without medium exchange, the cultures were carefully rinsed with PBS and stained with Giemsa dye and colonies containing more than 50 cells (Brown and Wouters, 1999) were counted to establish the survival curve.

Quantitative assay of angiogenesis in vitro

In vitro angiogenesis experiments were performed using the model described by Nicosia and Ottinetti (1990) with slight modifications. Male Wistar rats were anaesthetised with rompun/ketalar solution. Prior to dissection of the thoracic aorta a bolus of hirudin (3.5 mg kg⁻¹ i.v.) was injected into the animal to inhibit any trace of generated thrombin. The vessel was placed in survey medium consisting of Hank’s balanced salt solution containing 1% HSA, 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin, 0.25 μg ml⁻¹ fungizone. It was processed within 2 h following collection. The aorta was carefully cleaned from surrounding fibroadipose tissue and extensively washed in survey medium containing 2.5 times concentrated antibiotics and fungizone. Angiogenesis chambers consisted of agarose rings with 11 mm inner diameter. Each agarose ring was placed in one well from a six well dish. One and the thienopyridine, SR 25989, were a gift from Sanofi R&D systems (Minneapolis, MN, USA). Recombinant hirudin as follows: the fibrinogen solution (3 mg ml⁻¹) was from Sigma (St Louis, MO, USA). Cell culture medium (DMEM/HAM F12, with 1% HEPES; RPMI 1640) consisting of Hank’s balanced salt solution containing 1% HSA, 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin, 0.25 μg ml⁻¹ fungizone. It was processed within 2 h following collection. The aorta was carefully cleaned from surrounding fibroadipose tissue and extensively washed in survey medium containing 2.5 times concentrated antibiotics and fungizone. Angiogenesis chambers consisted of agarose rings with 11 mm inner diameter. Each agarose ring was placed in one well from a six well dish. One millimetre long aorta fragments were embedded in fibrin gels according to published procedures (Nicosia and Ottinetti, 1990) as follows: the fibrinogen solution (3 mg ml⁻¹ in PBS without Ca and Mg) was allowed to clot by adding α-thrombin (0.2 NIH U ml⁻¹ in 3 mM CaCl₂ solution) the bottom of each agarose well was coated with 100 μl of clotting fibrinogen solution and the fibrin gel was allowed to polymerise at 37°C. The aorta rings were transferred to fibrin gel and positioned on top of the gelling solution. The agarose wells was then filled with fibrinogen clotting solution. After polymerisation at 37°C, serum-free culture medium consisting in DMEM/HAM F12 supplemented with MgSO₄ (10 mM final), 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin and 2.5 μg ml⁻¹ fungizone, was added to each dish. In order to prevent fibrinolysis, α-amino caproic acid was added throughout the experiments. The medium was changed every second day and enumeration of newly formed vessels, arising from the intimal endothelium and the vasa vasorum of the aorta rings, was

Clonogenic assay

The effects of SR 25989 on cell survival was investigated in a clonogenic assay as follows: exponentially growing B16 F10 cells were used for the experiments. Single cell suspensions were prepared from B16 F10 cultures which had been submitted to increasing concentrations of SR 25989 (0 to 400 μM) for 4 h in medium containing 10% FCS. The suspensions were serially diluted in medium containing 10% FCS and the different B16 F10 cell dilutions were seeded in triplicate in 10 mm Petri dishes. After 7 to 10 days incubation without medium exchange, the cultures were carefully rinsed with PBS and stained with Giemsa dye and colonies containing more than 50 cells (Brown and Wouters, 1999) were counted to establish the survival curve.

Quantitative assay of angiogenesis in vitro

In vitro angiogenesis experiments were performed using the model described by Nicosia and Ottinetti (1990) with slight modifications. Male Wistar rats were anaesthetised with rompun/ketalar solution. Prior to dissection of the thoracic aorta a bolus of hirudin (3.5 mg kg⁻¹ i.v.) was injected into the animal to inhibit any trace of generated thrombin. The vessel was placed in survey medium consisting of Hank’s balanced salt solution containing 1% HSA, 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin, 0.25 μg ml⁻¹ fungizone. It was processed within 2 h following collection. The aorta was carefully cleaned from surrounding fibroadipose tissue and extensively washed in survey medium containing 2.5 times concentrated antibiotics and fungizone. Angiogenesis chambers consisted of agarose rings with 11 mm inner diameter. Each agarose ring was placed in one well from a six well dish. One millimetre long aorta fragments were embedded in fibrin gels according to published procedures (Nicosia and Ottinetti, 1990) as follows: the fibrinogen solution (3 mg ml⁻¹ in PBS without Ca and Mg) was allowed to clot by adding α-thrombin (0.2 NIH U ml⁻¹ in 3 mM CaCl₂ solution) the bottom of each agarose well was coated with 100 μl of clotting fibrinogen solution and the fibrin gel was allowed to polymerise at 37°C. Then, the aorta rings were transferred to fibrin gel and positioned on top of the gelling solution. The agarose wells was then filled with fibrinogen clotting solution. After polymerisation at 37°C, serum-free culture medium consisting in DMEM/HAM F12 supplemented with MgSO₄ (10 mM final), 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin and 2.5 μg ml⁻¹ fungizone, was added to each dish. In order to prevent fibrinolysis, α-amino caproic acid was added throughout the experiments. The medium was changed every second day and enumeration of newly formed vessels, arising from the intimal endothelium and the vasa vasorum of the aorta rings, was

Materials and methods

Animals, cells and materials

Male Wistar rats weighing between 200 and 250 g and male mice C57BL/6 weighing between 22 and 25 g, both kinds pathogen free, were obtained from Charles River (St Aubin, Les Elbeufs, France). Animal care and experimentation were in accordance with the institutional guidelines from the Ministère Français de l’Agriculture and The UKCCCR Guidelines (1998) for the welfare of animals in experimental neoplasia. All animal were fed a diet of water and The UKCCCR Guidelines (1998) for the welfare of animals in experimental neoplasia. All animal were fed a diet of water and The UKCCCR Guidelines (1998) for the welfare of animals in experimental neoplasia. All animal were fed a diet of.
performed every day for 8 to 10 days on an inverted microscope (magnification ×40, Nikon Diaphot TMD). Experiments in which occasionally smooth muscle cells or fibroblasts developed, recognisable because they formed cell layers instead of tubules, were systematically discarded.

Effect of the thienopyridine SR 25989 on spontaneous angiogenesis and angiogenesis induced by PDGF in vitro

SR 25989 in the range 1.5 to 150 μM was added to the culture medium, starting from day zero and at every medium change. The formation of neovessels was quantified according to criteria described by Nicosia and Ottinetti (1990). In a second set of experiments PDGF (1 ng ml⁻¹) was added from time zero and every second day until day 4. This growth factor presented to be the most potent to induce angiogenesis in this model as compared to bFGF (data not shown). Also, it had been shown previously that ticlopidine, another member of the thienopyridine family inhibits the release of PDGF from platelets (Morimoto et al., 1992). Due to the difference in reactivity between individual animals the number of spontaneously growing microvessels was heterogeneous between separate experiments. Nevertheless, for a given experiment this concentration of the growth factor was shown to enhance neovascularization 24 h thereafter.

Experimental spontaneous lung metastasis model

Exponentially growing B16 F10 cells detached by brief exposure to 0.05% Trypsin/0.02% EDTA were washed twice in complete medium and finally resuspended in Hank’s balanced salt solution. A single suspension of cells (depending on the experiment, five to 8.5 × 10⁶ cells, in 100 μl) was injected into the foot pad of C57BL/6 mice. This model was chosen in order to observe the effect of the drug on the development of the primary tumour and on the grounds of the high vascularisation of the foot pad. This makes this model closer to the ‘artificial pulmonary metastasis model’ which requires injection of the tumour cells directly in the tail vein than to the model implying implantation of tumour cells in the dorsal subcutaneous space. The injection schedule systematically alternated between mice in the control group and mice in the SR 25989 treated group to minimise differences which might be attributed to the duration of the injection protocol. At the end of the inoculation procedure the viability of B16 F10 cells assessed by Trypan blue dye exclusion was ≈85%. Animals were given either SR 25989 50 mg kg⁻¹ (equivalent to 120 μmoles kg⁻¹) or normal saline (control groups) intraperitoneally daily from the day of tumour inoculation to the time of sacrifice. The animals were alert throughout the experiment, did slowly gain weight during primary tumour development and significantly after amputation. The tumour bearing foot was amputated at day 23. At this time the mean tumour size reached 500 mm³. At distance from amputation one mouse from each series was sacrificed in order to assess the presence of metastases. This allowed to determine the time of sacrifice and autopsia before the development of metastases would cause dyspnoea. The mice were sacrificed around day 40. The tumours and inguinal lymph nodes were measured with a dial-caliper and the volumes calculated using the following formula:

\[ V = \frac{4}{3} \pi r^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]

\[ V = \frac{4}{3} \pi \left( \frac{d}{2} \right)^3 \]
The number and the size of metastatic foci on the pulmonary surface were macroscopically quantified. The primary tumour, inguinal lymph nodes and lungs were fixed in 10% formalin solution and embedded in paraffin.

Immunohistochemistry

Paraffin-embedded tumours, inguinal lymph nodes and lung sections were stained for vWF and for \( \alpha \)-SMA by standard indirect immunoperoxidase staining. Proteolytic predigestion of the formalin fixed tissue with 0.05% Trypsin for 30 min at room temperature was performed prior to incubation with anti-vWF antibodies. Primary antibodies were diluted according to the manufacturer’s recommendations and the tissue sections were incubated overnight at 4°C. Control staining was carried out in each case by replacing the primary antibody by matched isotypic non immune immunoglobulins. Next, the samples were incubated with the appropriate peroxidase conjugated secondary antibodies for 1 h at room temperature. Tissue labelling was revealed by 3,3’-diaminobenzidine staining, and the samples finally counterstained with haematoxylin (Harris formula) and mounted in Eukitt<sup>1</sup>.

Statistical analysis

The effects SR 25989 were compared by variance analysis followed by the Neuman–Keuls test, using the statistical software STATITCF (ITCF, Boigneville, France).

RESULTS

Inhibition of spontaneous angiogenesis in vitro by the thienopyridine SR 25989

The thienopyridine was added to angiogenesis chambers in serum-free medium at the following concentrations: 37.5, 75 and 150 \( \mu \)M, starting from day zero and at each medium change. As already published (Nicosia and Ottinetti, 1990), the fibrin gel stimulated an angiogenic process and microvascular sprouts developed with time. SR 25989 inhibited the formation of new vessels in a dose dependent manner and inhibition was almost complete for the higher concentration (Figure 1a). Evaluation of angiogenesis at day 7 as a function of SR 25989 concentration showed that half maximal inhibition was reached at less than 50 \( \mu \)M and was almost complete for concentrations over 60 \( \mu \)M SR 25989 (Figure 1b).

Effects of SR 25989 on angiogenesis in vitro induced by PDGF

PDGF (1 ng ml<sup>–1</sup>) was added starting from time zero of the experiment. This concentration of the growth factor enhanced the formation of spontaneous capillaries by 5 to 10 times over control values in a given experiment. When neovascularization was well established, at day 4, a low and a high concentration of SR 25989 were added to the culture medium and angiogenesis chambers incubated for one more day. When compared to the controls devoid of thienopyridine, the low concentration of SR 25989 (15 \( \mu \)M) inhibited further increase of newly formed microvessels (Figure 2) while the high concentration (150 \( \mu \)M) SR 25989 caused a total regression of the already established angiogenesis with a complete disappearance of the capillaries, leaving only dead isolated cells.
Inhibition of B16 F10 cells proliferation by SR 25989

The serum induced proliferation of B16 F10 cells was analysed in the presence of SR 25989 used at two doses encompassing the range of concentrations used in the preceding experiments. Control B16 F10 cells, as quantified by crystal violet staining of adherent cells, proliferated exponentially up to day 7 in the presence of 5 and 10% FCS and up to day 10 with 2% FCS (Figure 3). The apparent decrease in cell density observed at day 10 in the presence of 5 and 10% FCS was due to cell detachment caused by extremely high cell density. As previously shown for human endothelial cells and skin fibroblasts (Klein-Soyer et al., 1994, 1997) the lower concentration (37.5 µM) did not significantly affect B16 F10 cell proliferation as compared to corresponding control cultures. In contrast, the higher concentration (150 µM) totally inhibited the proliferation of the cells cultivated in 2 and 5% FCS and inhibited by over 90% the proliferation of B16 F10 cells cultivated in 10% FCS demonstrating cytostatic effects of this molecule in vitro (Figure 3).

Effects of SR 25989 on B16 F10 cells survival

In order to verify that SR 25989 should not have major toxic effects for cells in the range of concentration used for proliferation assays, the clonogenic survival of B16 F10 cells was analysed after exposure for 4 h to increasing concentrations of SR 25989 (50 to 400 µM). Up to 150 µM, SR 25989 did not decrease B16 F10 cells survival. For 200 µM the clonogenicity was only reduced by 20% thereafter it decreased rapidly and dose dependently reaching less than 5% for 400 µM (Figure 4).

SR 25989 does not affect the development of primary tumours and inguinal lymph nodes

When B16 F10 cells were inoculated into the foot pad of C57BL/6 mice melanic marks appeared as soon as day 7 after injection. Primary tumours developed equally in control and treated animals and the tumour bearing foot was amputated when tumours reached a mean volume of 500 mm³. Although tumours from the series treated with SR 25989 tended to develop at a lower rate a few days prior to amputation the average volume attained at this time was not significantly smaller than in the control series (data not shown). The overall vascularisation (macro and micrvascularisation) as assessed by vWF and α-SMA staining, was not different between the two series. The extent of necrotic areas, estimated on Hematoxylin-Eosin stained sections seemed however to be slightly larger in treated series although this difference did not appear to be statistically significant (data not shown). From the time of amputation most of animals developed inguinal lymphadenopathies at the site of the tumour bearing foot. The frequency of appearance of lymph nodes was similar between control and treated animals.

![Figure 5](https://example.com/figure5.png)

**Figure 5** Inhibition of the development of pulmonary metastases by SR 25989. (A) The number and the size of macroscopic pulmonary metastases were quantified at autopsy. Histogram left represents the mean of total macroscopic metastases. Histogram right represents the distribution of the metastases as a function of their diameter. Results are the mean ± s.e.m. for 11 control mice and 10 treated mice. One representative experiment out of three. (B) Paraffin embedded lung sections, Hematoxylin-Eosin staining. Left: control lung showing numerous coalescent metastases. Right: treated lung showing small peripheral or intrapulmonary metastases.
The health state of the mice was identical in control and SR 25989 treated animals (Figure 6 right). Inhibition of the development of spontaneous pulmonary metastasis by subcutaneously administered SR 25989

The average number of macroscopic pulmonary metastatic foci was diminished by 33% in animals treated with SR 25989 (Figure 5A left) when examined at the time of sacrifice. In addition when the metastases were distributed as a function of their diameter, it appeared that the size of the metastases was significantly greater in control animals and that most of the metastases from SR 25989 treated animals were classified in the category of smallest size (Figure 5A right). Histological sections of lungs from control mice showed large confluent metastases invading the entire pulmonary tissue and emerging at the surface of the lung while for SR 25989 treated mice the metastases remained significantly smaller and mainly localised at the pulmonary surface (Figure 5B). Immunostaining with a specific antibody to vWF, the specific marker of endothelial cells. Normal preexisting vessels or obstructed vascular lumens (data not shown). Angiogenesis was analysed using antibodies to vWF, the specific marker of endothelial cells. Normal preexisting vessels in the lung were totally absent in metastases of similar size from SR 25989 treated mice although the weight gain was slightly but not significantly lower in the latter group. Again no significant histological difference could be observed between the two series (data not shown).

DISCUSSION

The present results demonstrate that SR 25989, a member of the thienopyridine family, which has previously been shown to display anti-angiogenic properties in vitro (Klein-Soyer et al, 1994, 1997) also inhibits the development of metastases through an anti-angiogenic process in a murine pulmonary metastasis model.

Despite the availability of an ever-increasing number of potential tumoral prognostic markers and the use of aggressive therapies the prognosis of many cancer pathologies has to date only little been improved. This underlines the crucial need for defining new specific criteria integrating the vast diversity of the tumoral genetic alterations. One such strategy has since recent years been approached through the means of angiogenesis for several reasons: (i) the passage from normal tissue to hyperplasia and to tumorigenesis is related to an angiogenic switch (Hanahan and Folkman, 1996); (ii) angiogenesis is a dynamic balance between stimulators and inhibitors (Hanahan and Folkman, 1996; Iruela-Arispe and Dvorak, 1997). In the absence of angiogenesis the balance is in favour of the inhibitors which as such can account for tumour and micrometastases ‘dormancy’ (Folkman, 1995a; Holmgren et al, 1995); (iii) Due to its specific characteristics, the tumour vasculature constitutes a common feature between the various tumoral tissues (Denekamp et al, 1998). These data have opened an extensive field of investigation to find new anti-angiogenic molecules. Among these molecules the thienopyridine ticlopidine has been shown to reduce the progression of non proliferative diabetic retinopathy (TIMAD Study Group, 1990; Guillausseau, 1994) and to inhibit pulmonary metastasis development in mice (Kohga et al, 1981; Bando et al, 1984). These results prompted us to evaluate the potential anti-angiogenic properties of another member of the thienopyridine family SR 25989 which is an enantionomer of the anti-aggregant clopidogrel (Plavix) but which lacks anti-aggregant activity.

We have previously shown that SR 25989 inhibited spontaneous and growth factor induced endothelial cell migration and prolifera-

Figure 6 Representative immunohistochemistry of pulmonary metastases from control and SR 25989 treated mice. Paraffin embedded lung sections were labelled with anti-von Willebrand factor antibody (vWF) or anti-α-Smooth muscle actin antibody (α-SMA) as described in Materials and Methods. An intense labelling for vWF can be seen in a metastasis from a control lung (upper left), this labelling is totally absent in a metastasis of identical size from a treated lung (lower left). α-SMA labelling in the metastases from adjacent sections of the lungs from control and treated mice (right).
tion in a mechanical wound repair model (Klein-Soyer et al., 1994). Now, the quantitative angiogenesis assay (Nicosia and Ottinetti, 1990) allowed to further assess the anti-angiogenic properties of the thienopyridine in vitro: (i) SR 25989 inhibited in a dose dependent manner the spontaneous microvesSEL formation from rat aorta fragments embedded in a fibrin gel; (ii) It caused the regression of microvesSEL development induced by the growth factor PDGF. Hence, we went on evaluating the anti-angiogenic effects of this thienopyridine in a murine pulmonary metastasis model.

High concentrations of SR 25989 displayed cytotoxic effects on the proliferation of B16 F10 cells in vitro, however it apparently did not significantly affect the development of the primary tumour at the therapeutic doses essayed in mice as far as the size of the tumour was concerned. For principles of animal care and comfort it was not possible to fully analyse the slight inhibitory effect observed on SR 25989 treated tumour right before amputation. That SR 25989, which potentially inhibits angiogenesis, did not alter tumour growth and lymph node development could be explained by the high vascularisation of the foot pad. This site of injection has been chosen on this purpose to favour tumour cell shedding in the circulation thus allowing distant metastasis development. The already existing vascularisation may be sufficient to explain the regular growth of primary tumours and development of proximal lymph nodes perhaps by vessel cooption (Holash et al., 1999). Alternatively, considering the initially high number of tumour cells injected in the foot pad and subsequently isolated tumour cells shed in the circulation, the balance between angiogenesis activators and inhibitors may have been different in the primary tumour and in developing metastases. Thus the available concentration of SR 25989 could have been insufficient to efficiently inhibit angiogenesis activators participating to primary tumour development. Although the thienopyridine did not significantly hinder primary tumour growth, a striking effect of SR 25989 could be observed on the development of pulmonary metastases. Both the number and the size of the metastases were reduced in animals treated with the thienopyridine. While in lungs from control animals numerous coalescent metastases were observed, the lungs from SR 25989 treated animals contained only few metastases and these were significantly smaller. In large metastases from control mice immature vascularisation could be visualized by vWF immunostaining. This type of labelling was always absent in lung sections from SR 25989 treated animal. This reinforces the fact that SR 25989 inhibits distant metastasis development through an anti-angiogenic process. Such a paradoxical effect in which an angiogenic process is directly opposed to the angiogenic process itself has been previously observed (Butterfield et al., 1998). SR 25989 seems to show valuable anti-angiogenic effects both in vitro and in vivo and thus deserves further evaluation in view of its potential use as an adjuvant treatment of cancer therapy in humans.

ACKNOWLEDGEMENTS
The authors gratefully acknowledge, the excellent technical assistance of Marlene Ehret, Francine Noel and Betty Heyd and the helpful advises in immunohistology of Monique Freund and Michele Finck. The authors also thank Dr J-M Herbert for providing the mouse melanoma B16 F10 cell line. Part of this project was financially supported by the Association pour la Thérapie Génique des Cancers (ATGC). Part of this work has been presented at the 2nd seminar on Angiogenesis, February 8th 2001, Strasbourg, France and at the 92nd annual meeting of the American Association for Cancer Research, March 23 – 28, 2001, New Orleans, LA, USA.

REFERENCES

Barina N (1999) New type of blood vessel found in tumors. Science 285: 284 – 289
Bando H, Yamashita T, Tsubura E (1990) Effects of antiplatelet agents on pulmonary metastasis. Gann 75: 284 – 291
Bornstein P (1995) Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin-1. J Cell Biol 130: 503 – 506
Brooks PC, Clark RA, Cheresch DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 560 – 571
Brown JM, Wouda G, Grootenbergh P (1999) Apoptosis facilitates and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391 – 1399
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249 – 257
Cazenave JP, Herbert JM (1992) Utilisation de derives de tetrahydrothienopyridines comme inhibiteurs de l'angiogenèse. Patent No 92 400389.
Denekamp J, Dasu A, Waite A (1998) Vascular and microenvironmental gradients: the missing links in novel approaches to cancer therapy. Advan Enzyme Regul 38: 281 – 299
Deplanque G, Harris AL (2000) Anti-angiogenic agents: clinical trial design and therapies in development. Eur J Cancer 36: 1713 – 1724
Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W (2001) Intratumoral administration of SR 25989 and Dr I Fidler for generously providing the mouse melanoma B16 F10 cell line. Part of this project was financially supported by the Association pour la Thérapie Génique des Cancers (ATGC). Part of this work has been presented at the 2nd seminar on Angiogenesis, February 8th 2001, Strasbourg, France and at the 92nd annual meeting of the American Association for Cancer Research, March 23 – 28, 2001, New Orleans, LA, USA.
DiPietro LA (1997) Thrombospondin as a regulator of angiogenesis. In Regulation of Angiogenesis, Goldberg ID, Rosen EM (eds) pp. 295 – 314. Basel: Birkhäuser Verlag
Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing, Lab Invest 57: 673 – 686
Eskewowitz RA, Mulliken JB, Folkman J (1992) Interferon α-2a therapy for life-threatening hemangiomias of infancy, N Engl J Med 326: 1456 – 1463
Fidler IJ (1973) Selection of successive tumor lines for metastases. Nature New Biol 242: 148 – 149
Folkman J (1990) What is evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4 – 6
Folkman J (1995a) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27 – 31
Folkman J (1995b) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757 – 1763
Gervaz P, Scholl B, Padrus, Y. Gillet M (2000) Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470. Liver 20: 108 – 113
Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Anal Biochem 159: 109 – 113
Griggs DW, Shannon KE, Keene JL, Settle SL, Duffin TD, Nichols MA, Schroeter S, Nichols GA, Westlin WF (2001) Anti-metastatic efficacy mediated by peptidomimetic α/β₃ integrin antagonist in orthopic and experimental models. Proc 92nd Ann Meet Am Assoc Cancer Res 42: 263 (Abstract #1420)
Guillausseau PJ (1994) Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms. Diabeber Metab 20: 219 – 228
Guthel JC, Campbell TN, Piece PR, Watkins JD, Huse WD, Bodkin DJ, Chersch DA (2000) Targeted antiangiogenic therapy for cancer using Vaxitin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056 – 3061
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353 – 364
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression and the angiogenic switch during tumorigenesis. Clin Cancer Res 5: 1460 – 1467
Klein-Soyer C, Cazenave J-P, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing, Lab Invest 57: 673 – 686
Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Pegram M, Slamon D (2000) Biological rational for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27: 13 – 19
Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewiecz M, Koike K, Park KR, Ferrara N, Jain R, Suit HD, Boucher Y (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565 –5570
Leinens, S, De Clercq E, Neumann F (2001) Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61: 253 – 270
Luscinias FW, Lawler J (1994) Integrins as dynamic regulators of vascular function. JASEB 78: 929 – 938
Lush RM, Rudek MA, Figg WD (1999) Review of three new agents that target angiogenesis, matrix metalloproteinases, and cyclo-dependent kinases. Cancer Control 6: 459 – 465
Maione TE, Gray GS, Petrov J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ (1990) Inhibition of angiogenesis by recombinant human platelet 4 and related peptides. Science 247: 77 – 79
Mantiotis AL, Folberg R, Hess A, Seftor EA, Gerdner LMG, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasulogenenic mimicry. Am J Pathol 1555: 739 – 752
Morimoto S, Shiraishi T, Fukuo K, Koh E, Kittano S, Yasuda O, Tamatami M, Ogihara T (1992) Effect of ticlopidine on PDGF release from platelets. Curr Ther Res 52: 382 – 385
Nicosia RF, Ottinetti A (1990) Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 63: 115 – 122
Ngi PK, Chang YJ (1991) A novel one-step purification of human z-thrombin after direct activation of crude prothrombin enriched from plasma. Biochem J 280: 805 – 808
Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ (2000) Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37: 209 – 218
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315 – 328
O’Reilly MS, Boehm T, Shing Y, Fuku N, Vasis S, Lane WS, Flynn E, Birkead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 86: 277 – 285
Pegram M, Slamon D (2000) Biological rational for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27: 13 – 19
Pepper MS, Mandriota SJ, Vassali J, Orlic L, Montesano R (1996) Angiogenesis-regulating cytokines: activities and interactions. In Attempts to Understand Metastasis Formation II, Vol 213, Günther U, Birchmeier W (eds) pp. 31 – 67, Berlin: Springer Verlag
Perkins DJ (1996) Regulation of tumor growth and metastasis by thrombospondin-1. JASEB 78: 1108 – 1113
Sage EH, Bornstein (1991) Extracellular proteins that modulate cell-matrix interactions. J Biol Chem 266: 14831 – 14834
Sage EH (1997) Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol 7: 182 – 186
Savill J, Hogg N, Ren Y, Haslett C (1992) Thrombospondin cooperates with CD3 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90: 1513 – 1522
Shalinsky DR, Brekken R, Zhou H, McDermott CD, Forryth P, Edwards D, Margossiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K (1999) Broad antitumor and antiangiogenic activities of AG3340 a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878: 236 – 270
The TIMAD Study Group (1990) Ticlopidine treatment increases the progression of proliferative diabetic retinopathy. Arch Ophthalmol 108: 1577 – 1583
Soti F, Rohr S, Mechina A, Cazeneve J-P (2001) Effects of thienopyridine products on angiogenesis in rats. Int Angiol 20: 266
UKCCCR Guidelines (1998) United Kingdom Coordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1 – 10
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen J, Hennesquin LF, Stokes ESE, Curry B, Wadsworth PF, Richmond GHP (2001) Pharmacological efficacy of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in rat. Proc 92nd Ann Meet Am Assoc Cancer Res 42: 583 (Abstract #3126)